Form 13-F position report

ENANTA PHARMACEUTICALS INC

Reported by VANGUARD GROUP INC

ENTA CUSIP 29251M106 Manager CIK 0000102909

Reported 1,800,363 shares, down 56,656 (3.1%) from the prior quarter.

Reported value 25.1%; share count -3.1% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q3 2021
Shares 1,800,363 Quarter-end amount reported
Reported value $102,278,000 Fair value at quarter end
Consecutive quarters held 34 Through Q3 2021

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-03-31 93642000
2021-06-30 81727000
2021-09-30 102278000
2021-12-31 121586000
2022-03-31 113122000
2022-06-30 71694000
2022-09-30 76609000
2022-12-31 70812232
2023-03-31 62152357
2023-06-30 36512145
2023-09-30 18548009
2023-12-31 16879526
2024-03-31 33664242
2024-06-30 25089038
2024-09-30 20532133
2024-12-31 11408944
2025-03-31 11081031
2025-06-30 14943640
2025-09-30 23207783
2025-12-31 36299291

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for ENANTA PHARMACEUTICALS INC held by VANGUARD GROUP INC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2025 Added 2,301,794 +362,965 (18.7%) < 0.01% $36,299,291 2026-01-29
Q3 2025 Reduced 1,938,829 -37,843 (-1.9%) < 0.01% $23,207,783 2025-11-07
Q2 2025 Reduced 1,976,672 -30,761 (-1.5%) < 0.01% $14,943,640 2025-08-11
Q1 2025 Added 2,007,433 +23,269 (1.2%) < 0.01% $11,081,031 2025-05-09
Q4 2024 Added 1,984,164 +2,298 (0.1%) < 0.01% $11,408,944 2025-02-11
Q3 2024 Added 1,981,866 +47,476 (2.5%) < 0.01% $20,532,133 2024-11-13
Q2 2024 Added 1,934,390 +6,312 (0.3%) < 0.01% $25,089,038 2024-08-13
Q1 2024 Added 1,928,078 +134,292 (7.5%) < 0.01% $33,664,242 2024-05-10
Q4 2023 Added 1,793,786 +133,266 (8.0%) < 0.01% $16,879,526 2024-02-14
Q3 2023 Reduced 1,660,520 -45,655 (-2.7%) < 0.01% $18,548,009 2023-11-14
Q2 2023 Added 1,706,175 +169,272 (11.0%) < 0.01% $36,512,145 2023-08-14
Q1 2023 Added 1,536,903 +14,714 (1.0%) < 0.01% $62,152,357 2023-05-15
Q4 2022 Added 1,522,189 +45,279 (3.1%) < 0.01% $70,812,232 2023-02-10
Q3 2022 Reduced 1,476,910 -39,779 (-2.6%) < 0.01% $76,609,000 2022-11-14
Q2 2022 Reduced 1,516,689 -72,535 (-4.6%) < 0.01% $71,694,000 2022-08-12
Q1 2022 Reduced 1,589,224 -36,685 (-2.3%) < 0.01% $113,122,000 2022-05-13
Q4 2021 Reduced 1,625,909 -174,454 (-9.7%) < 0.01% $121,586,000 2022-02-14
Q3 2021 Reduced 1,800,363 -56,656 (-3.1%) < 0.01% $102,278,000 2021-11-12
Q2 2021 Reduced 1,857,019 -41,655 (-2.2%) < 0.01% $81,727,000 2021-08-13
Q1 2021 Added 1,898,674 +98,095 (5.4%) < 0.01% $93,642,000 2021-05-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

159 managers reported ENANTA PHARMACEUTICALS INC for Q3 2021.

Managers reporting ENANTA PHARMACEUTICALS INC in Q3 2021.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Reduced 3,595,053 -76,953 < 0.01% $204,237,000 30 qtrs
FARALLON CAPITAL MANAGEMENT LLC Unchanged 1,995,000 0 0.53% $113,336,000 17 qtrs
ARMISTICE CAPITAL LLC Reduced 1,836,000 -164,000 1.77% $104,303,000 22 qtrs
VANGUARD GROUP INC This report Reduced 1,800,363 -56,656 < 0.01% $102,278,000 34 qtrs
STATE STREET CORPORATION Added 1,072,182 +18,107 < 0.01% $60,911,000 33 qtrs
FIRST MANHATTAN CO Added 969,736 +936,536 0.2% $55,090,000 21 qtrs
NORTHERN TRUST CORPORATION Added 959,048 +310,246 < 0.01% $54,483,000 34 qtrs
Krensavage Asset Management LLC Reduced 936,777 -2,873 16.69% $53,218,000 27 qtrs
RENAISSANCE TECHNOLOGIES LLC Reduced 756,585 -41,143 0.06% $42,982,000 23 qtrs
DIMENSIONAL FUND ADVISORS LP Reduced 610,866 -33,922 0.01% $34,703,000 27 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2021
Filed
November 12, 2021
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
18,727
None
1,781,636

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.